What one share of HCW Biologics holds
HCW Biologics Inc. (“HCW Biologics” or the “Company”) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. We have created novel compounds that represent a new class of drugs that we believe have the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia.
HCW Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $8.58 |
|---|---|
| Profit | −$27.32 |
| Cash and investments | $0.46 |
| Debt | $4.21 |
| Book value | $4.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$358.23 | $9.45 | −$537.70 | — | −$936.23 |
| 2021 | — | −$164.46 | $0.60 | −$140.94 | — | $343.39 |
| 2022 | — | −$99.83 | $68.84 | −$138.43 | — | $249.35 |
| 2023 | — | −$166.96 | $41.43 | −$191.82 | — | $89.68 |
| 2024 | — | −$185.75 | $1.62 | −$89.64 | — | −$36.48 |
| 2025 | $0.16 | −$63.78 | $0.00 | −$38.30 | — | $2.46 |
Common questions about HCW Biologics
How much does one share of HCW Biologics earn?
Over the last 12 months, HCW Biologics lost $27.32 for each share on $8.58 of sales.
Does HCW Biologics pay a dividend?
HCW Biologics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is HCW Biologics’s book value per share?
HCW Biologics’s book value is $4.59 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of HCW Biologics have?
Each share of HCW Biologics has $0.46 of cash and investments and $4.21 of debt, as of June 30, 2026.
Has HCW Biologics bought back shares?
HCW Biologics’s share count rose about 1670% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.